

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	7	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	8	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	9	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	10	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	11	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	12	OCT 19	E-mail format enhanced
NEWS	13	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	14	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	15	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	16	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	17	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	18	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	19	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	20	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	21	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	22	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	23	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	24	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	25	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	26	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	27	DEC 18	CA/CAplus patent kind codes updated
NEWS	28	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	29	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	30	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:50:38 ON 27 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:50:48 ON 27 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

DICTIONARY FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s losartan/cn

L1 1 LOSARTAN/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.20

5.41

FILE 'CAPLUS' ENTERED AT 13:51:00 ON 27 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Dec 2006 VOL 146 ISS 1

FILE LAST UPDATED: 26 Dec 2006 (20061226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 11/thu

2606 L1  
841505 THU/RL  
L2 1882 L1/THU  
(L1 (L) THU/RL)

=> s cancer? or neoplas? or tumor?

316388 CANCER?  
474891 NEOPLAS?  
452809 TUMOR?  
L3 750228 CANCER? OR NEOPLAS? OR TUMOR?

=> s 12 (L) 13

L4 9 L2 (L) L3

=> s 14 not py>2000

6644846 PY>2000  
L5 0 L4 NOT PY>2000

=> d 14 ibib 19

9 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE  
The answer numbers requested are not in the answer set.  
ENTER ANSWER NUMBER OR RANGE (1):1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:101964 CAPLUS <<LOGINID::20061227>>  
DOCUMENT NUMBER: 144:184652  
TITLE: Novel pathways in the etiology of cancer, and  
treatment methods  
INVENTOR(S): Benz, Christopher C.  
PATENT ASSIGNEE(S): Buck Institute for Age Research, USA  
SOURCE: U.S. Pat. Appl. Publ., 49 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024691	A1	20060202	US 2005-90546	20050324
PRIORITY APPLN. INFO.:			US 2004-556774P	P 20040325
			US 2004-580534P	P 20040616
			US 2004-629691P	P 20041119

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1284893 CAPLUS <<LOGINID::20061227>>  
DOCUMENT NUMBER: 144:285876

TITLE: TGF- $\beta$  and TNF- $\alpha$  producing effects of  
losartan and amlodipine on human mononuclear cell  
culture  
AUTHOR(S): Kaynar, Kubra; Ulusoy, Sukru; Ovali, Ercument;  
Vanizor, Birgul; Dikmen, Tamer; Gul, Semih  
CORPORATE SOURCE: Department of Nephrology, School of Medicine,  
Karadeniz Technical University, Trabzon, Turk.  
SOURCE: Nephrology (2005), 10(5), 478-482  
CODEN: NEPHF2; ISSN: 1320-5358

PUBLISHER: Blackwell Publishing Asia Pty Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1213085 CAPLUS <<LOGINID::20061227>>  
DOCUMENT NUMBER: 144:225211  
TITLE: G protein-coupled receptors as targets for drug  
discovery  
AUTHOR(S): Esbenshade, Timothy A.  
CORPORATE SOURCE: Neuroscience Research, Global Pharmaceutical Research  
and Development, Abbott Laboratories, Abbott Park, IL,  
USA  
SOURCE: Drug Discovery Series (2006), Volume 4, Issue G  
Protein-Coupled Receptors in Drug Discovery, 15-36.  
CRC Press LLC: Boca Raton, Fla.  
CODEN: DDSRBS  
DOCUMENT TYPE: Conference; General Review  
LANGUAGE: English  
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1188658 CAPLUS <<LOGINID::20061227>>  
DOCUMENT NUMBER: 144:16589  
TITLE: Antiproliferative activity of angiotensin II receptor  
blocker through cross-talk between stromal and  
epithelial prostate cancer cells  
AUTHOR(S): Uemura, Hiroji; Ishiguro, Hitoshi; Nagashima, Yoji;  
Sasaki, Takeshi; Nakaigawa, Noboru; Hasumi, Hisashi;  
Kato, Shingo; Kubota, Yoshinobu  
CORPORATE SOURCE: Department of Urology and Second Department of  
Pathology, Yokohama City University Graduate School of  
Medicine, Yokohama, Japan  
SOURCE: Molecular Cancer Therapeutics (2005), 4(11), 1699-1709  
CODEN: MCTOCF; ISSN: 1535-7163  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:291659 CAPLUS <<LOGINID::20061227>>  
DOCUMENT NUMBER: 143:323408  
TITLE: Blockage of angiotensin II type I receptor decreases  
the synthesis of growth factors and induces apoptosis  
in C6 cultured cells and C6 rat glioma  
AUTHOR(S): Arrieta, O.; Guevara, P.; Escobar, E.;  
Garcia-Navarrete, R.; Pineda, B.; Sotelo, J.  
CORPORATE SOURCE: Neuroimmunology Unit of the National Institute of  
Neurology and Neurosurgery of Mexico, Mexico City,  
14269, Mex.  
SOURCE: British Journal of Cancer (2005), 92(7), 1247-1252  
CODEN: BJCAAI; ISSN: 0007-0920  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:862779 CAPLUS <<LOGINID::20061227>>  
 DOCUMENT NUMBER: 139:345909  
 TITLE: Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression  
 INVENTOR(S): Suthanthiran, Manikkam; Maluccio, Mary  
 PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA  
 SOURCE: U.S., 7 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6641811	B1	20031104	US 2001-781146	20010209
US 2004067233	A1	20040408	US 2003-627408	20030725
PRIORITY APPLN. INFO.:			US 2000-181485P	P 20000210
			US 2001-781146	A3 20010209
REFERENCE COUNT:	18	THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:849376 CAPLUS <<LOGINID::20061227>>  
 DOCUMENT NUMBER: 137:358120  
 TITLE: Compositions and methods for treating colorectal polyps and cancer  
 INVENTOR(S): Tamura, Masaaki  
 PATENT ASSIGNEE(S): Vanderbilt University, USA  
 SOURCE: PCT Int. Appl., 143 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087503	A2	20021107	WO 2002-US13383	20020426
WO 2002087503	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2002311859 A1 20021111 AU 2002-311859 20020426 US 2003083339 A1 20030501 US 2002-133056 20020426 PRIORITY APPLN. INFO.:				
			US 2001-286621P	P 20010426
			WO 2002-US13383	W 20020426

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:209554 CAPLUS <<LOGINID::20061227>>  
 DOCUMENT NUMBER: 135:298256  
 TITLE: Angiotensin II receptor blockade: a novel strategy to prevent immunosuppressant-associated cancer progression  
 AUTHOR(S): Maluccio, M.; Sharma, V.; Lagman, M.; Konijn, G.; Suthanthiran, M.  
 CORPORATE SOURCE: Department of Transplantation and Extracorporeal

Therapy, Division of Nephrology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA

SOURCE: Transplantation Proceedings (2001), 33(1-2), 1820-1821  
CODEN: TRPPA8; ISSN: 0041-1345

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:90617 CAPLUS <<LOGINID::20061227>>

DOCUMENT NUMBER: 135:165893

TITLE: Interaction between paracrine tumor necrosis factor-alpha and paracrine angiotensin II during myocardial ischemia

AUTHOR(S): Frolkis, Inna; Gurevitch, Jacob; Yuhas, Yael; Iaina, Adrian; Wollman, Yoram; Chernichovski, Tamara; Paz, Yosef; Matsa, Menachem; Pevni, Dimitri; Kramer, Amir; Shapira, Itzhak; Mohr, Rephael

CORPORATE SOURCE: Department of Thoracic and Cardiovascular Surgery, Tel Aviv Medical Center, Tel Aviv-Jaffa, Israel

SOURCE: Journal of the American College of Cardiology (2001), 37(1), 316-322  
CODEN: JACCDI; ISSN: 0735-1097

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.39	26.80

FILE 'REGISTRY' ENTERED AT 13:52:36 ON 27 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6  
DICTIONARY FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 114798-26-4 REGISTRY  
 ED Entered STN: 11 Jun 1988  
 CN 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol  
 CN DUP 89  
 CN Lortaan  
 CN Losartan  
 MF C22 H23 Cl N6 O  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB\*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, MEDLINE, MRCK\*, PATDPASPC, PROMT, PROUSDDR, RTECS\*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2599 REFERENCES IN FILE CA (1907 TO DATE)  
 35 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 2606 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
2.34	29.14

FILE 'CAPLUS' ENTERED AT 13:52:58 ON 27 DEC 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Dec 2006 VOL 146 ISS 1  
FILE LAST UPDATED: 26 Dec 2006 (20061226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 11

L6 2606 L1

=> s 16 and 12

L7 1882 L6 AND L2

=> s 16 (L) 12

L8 1882 L6 (L) L2

=> s 16 (L) 13

L9 10 L6 (L) L3

=> s 19 not py>2000

6644846 PY>2000

L10 0 L9 NOT PY>2000

=> s 19 not 14

L11 1 L9 NOT L4

=> d ibib

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:300291 CAPLUS <<LOGINID::20061227>>

DOCUMENT NUMBER: 142:351308

TITLE: Contrast agents for optical imaging in diagnosis and follow-up of treatment for colorectal cancer

INVENTOR(S): Klaveness, Jo; Johannesen, Edvin; Tolleshaug, Helge

PATENT ASSIGNEE(S): Amersham Health AS, Norway

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030266	A2	20050407	WO 2004-NO287	20040928
WO 2005030266	A3	20050616		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1667734	A2	20060614	EP 2004-775070	20040928
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			



PRIORITY APPLN. INFO.:

NO 2003-4350  
WO 2004-NO287

A 20030929  
W 20040928

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.55	32.69

FULL ESTIMATED COST

FILE 'PCTFULL' ENTERED AT 13:53:50 ON 27 DEC 2006  
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:	19 DEC 2006	<20061219/UP>
MOST RECENT UPDATE WEEK:	200650	<200650/EW>
FILE COVERS 1978 TO DATE		

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

=> s losartan lortaan

1654 LOSARTAN  
1 LOSARTANS  
1654 LOSARTAN  
(LOSARTAN OR LOSARTANS)  
2 LORTAAN  
L12 0 LOSARTAN LORTAAN  
(LOSARTAN(W)LORTAAN)

=> s losartan or lortaan

1654 LOSARTAN  
1 LOSARTANS  
1654 LOSARTAN  
(LOSARTAN OR LOSARTANS)  
2 LORTAAN

L13 1654 LOSARTAN OR LORTAAN

=> s cancer? or tumor? or neoplas?

84143 CANCER?  
70103 TUMOR?  
24453 NEOPLAS?

L14 104590 CANCER? OR TUMOR? OR NEOPLAS?

=> s l13 and l14

L15 952 L13 AND L14

=> s l15 not py>2000

683677 PY>2000

L16 101 L15 NOT PY>2000

=> s l14/ab or l14/clm

13958 CANCER?/AB  
8518 TUMOR?/AB  
1579 NEOPLAS?/AB  
24396 CANCER?/CLM  
16314 TUMOR?/CLM  
3989 NEOPLAS?/CLM

L17 40137 (CANCER?/AB OR TUMOR?/AB OR NEOPLAS?/AB) OR (CANCER?/CLM OR  
TUMOR?/CLM OR NEOPLAS?/CLM)

```
=> s 113/clm or 113/ab
      334 LOSARTAN/CLM
      0 LORTAAN/CLM
      33 LOSARTAN/AB
      1 LOSARTANS/AB
      33 LOSARTAN/AB
      ((LOSARTAN OR LOSARTANS)/AB)
      0 LORTAAN/AB
L18      337 (LOSARTAN/CLM OR LORTAAN/CLM) OR (LOSARTAN/AB OR LORTAAN/AB)
```

```
=> s 118 and 117
L19      86 L18 AND L17
```

```
=> s 119 not py>2000
      683677 PY>2000
L20      2 L19 NOT PY>2000
```

```
=> d ibib kwic 1-2
```

```
L20      ANSWER 1 OF 2      PCTFULL      COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:      2000040227 PCTFULL      ED 20020515 <<LOGINID::20061227>>
TITLE (ENGLISH):      METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE
                        ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX
TITLE (FRENCH):      PROCEDES DE TRAITEMENT D'ETATS ASSOCIES A
                        L'ACCUMULATION D'UN EXCEDENT DE MATRICE EXTRACELLULAIRE
INVENTOR(S):      NOBLE, Nancy, A.;
                        BORDER, Wayne, A.;
                        LAWRENCE, Daniel, A.
PATENT ASSIGNEE(S):      UNIVERSITY OF UTAH;
                        AMERICAN NATIONAL RED CROSS;
                        NOBLE, Nancy, A.;
                        BORDER, Wayne, A.;
                        LAWRENCE, Daniel, A.
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:      Patent
PATENT INFORMATION:
```

	NUMBER	KIND	DATE
	WO 2000040227	A2	20000713
DESIGNATED STATES			
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US179	A	20000105
PRIORITY INFO.:	US 1999-60/114,795		19990105

```
CLMEN      Renin inhibitor Ro42-5892 (Hoffinan-LaRoche, Basel, Switzerland),
            Losartan (Merck
            Phannaceuticals, West Point, PA), Enalapril't' (Sigma Chemical Co., St.
            Louis, MO, Prod. No.
            E6888), or TGFP 1 neutralizing antibody (R & . . . R & D Systems, # AB
            IO 1 Q
            1 5 10-5 M Enalapril'm (Sigma Chemical Co., St. Louis, MO)
            IO-' M Losartan]' (Merck Pharmaceuticals, West Point, PA)
            These inhibitors were added at zero time with 1 V M human recombinant
            renin
            (Hoffinan-LaRoche).
            As shown in. . . Angiotensinogen (Ro 42-5892), blocking
            Angiotensin I conversion to Angiotensin II (Enalapril't') and blocking
```

binding of Angiotensin H  
to its type I receptor (Losartan]'), does not reduce the  
renin-induced increase in TGFP production.  
These results demonstrate for the first time an alternative pathway in  
which. . . Demonstration that Renin Upregulation of TGFD is not  
mediated through Renin Epz=atic  
Activily or Angiotensin H  
Renin inhibitor Ro42-5892 (Hoffinan-LaRoche, Basel, Switzerland),  
Losartan]' (Merck  
Phan-naccuticals, West Point, PA), Enalapril (Sigma Chemical Co., St.  
Louis, MO, Prod. No.  
E6888), or TGFP I neutralizing antibody (R & . . . renin:  
1 0 -' M Renin Inhibitor R042-5 892 (Hoffman-LaRoche)  
1 0' M Enalapril (Sigma Chemical Co., St. Louis, MO)  
1 0' M Losartan (Merck Pharmaceuticals, West Point, PA)

34  
Controls included neutralizing antibody to TGFP (ATG) and control IgG  
(TgG)  
These inhibitors were added at zero. . . Angiotensinogen (RO  
42-5892), blocking  
Angiotensin I conversion to Angiotensin Il (Enalapril') and blocking  
binding of Angiotensin ]El  
to its type I receptor (Losartan]'), does not reduce the  
renin-induced increase in TGFP production.

0.  
These results provide additional evidence that renin upregulates TGFP  
production by  
human mesangial. . . high plasma renin as are observed with  
therapeutic Angiotensin Il blockade. Thus, the  
use of therapeutic agents such as Enalapril'm or Losartan]'  
for Angiotensin blockade may not be  
optimal as treatment agents because of resulting high renin levels,  
preventing a therapeutic  
reduction in TGFP.. . .

. . .  
of claim 4 wherein said ACE inhibitor is Enalapril.

42

. The method of claim 4 wherein said All receptor antagonist is  
Losartan.

. . .  
acute respiratory distress syndrome (ARDS), diabetes, diabetic  
kidney disease, liver fibrosis, kidney fibrosis, lung fibrosis, post  
infarction cardiac fibrosis,  
fibrocystic diseases, fibrotic cancer, post myocardial  
infarction, left ventricular hypertrophy,  
pulmonary fibrosis, liver cirrhosis, veno-occlusive disease, post-spinal  
cord injury, post-retinal  
and glaucoma surgery, post-angioplasty restenosis, renal. . .

L20 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univention on STN  
ACCESSION NUMBER: 1999018956 PCTFULL ED 20020515 <<LOGINID::20061227>>  
TITLE (ENGLISH): 12(S)-HETE RECEPTOR BLOCKERS  
TITLE (FRENCH): INHIBITEURS DU RECEPTEUR DE 12(S)-HETE  
INVENTOR(S): NATARAJAN, Rama, Devi;  
NADLER, Jerry, L.  
PATENT ASSIGNEE(S): CITY OF HOPE  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9918956	A1	19990422

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC  
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU  
 SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM  
 KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE  
 CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ  
 CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US21570 A 19981014  
 PRIORITY INFO.: US 1997-60/062,335 19971015

ABEN . . . The 12-lipoxygenase product, 12(S)-HETE, mediates  
 hyperproliferative and hyperplastic responses  
 seen in atherosclerosis, diabetes, Parkinson's disease, Alzheimer's,  
 stroke-induced nerve damage and  
 cancer. 12-HETE also mediates inflammation and cell death in  
 some cell systems, particularly  
 B-islet cells of the pancreas. The present invention. . .  
 ABFR . . . dans l'atherosclerose, le diabete, la maladie de  
 Parkinson, la maladie d'Alzheimer, les lesions nerveuses induites par un  
 ictus et le cancer. 12-HETE  
 induit egalement l'inflammation et la mort cellulaire dans certains  
 systemes cellulaires, notamment  
 les ilots pancreatiques B. La presente invention. . .

CLMEN. . . wherein the disease  
 is atherosclerotic cardiovascular disease, glucose-  
 induced complications of diabetes, Parkinson's disease,  
 Alzheimer's disease, stroke-induced nerve damage,  
 cytokine induced inflammatory disease or tumor cell  
 growth or metastasis.

20 The method of claim 19, wherein the 12-HETE  
 receptor blocker is selected from the group consisting  
 of DuP654, Losartan, pertussis toxin, a 12(S)-HETE  
 analog, an antibody to the 12(S)-HETE receptor, a  
 peptide which binds to the 12(S)-HETE receptor and a  
 peptide analog. . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	9.53	42.22

STN INTERNATIONAL LOGOFF AT 13:56:46 ON 27 DEC 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x